|
Mutation Information
|
Mutation Site
|
M41L |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.N348I+rt.M41L |
|
Viral Reference
|
K03455.1
|
|
Relevant Drug
|
thymidineanalogue (TAMs) |
|
Country
|
UK |
Literature Information
|
PubMed PMID
|
18052601
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2007 |
|
Journal
|
PLoS medicine |
|
Title
|
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. |
|
Author
|
Yap SH,Sheen CW,Fahey J,Zanin M,Tyssen D,Lima VD,Wynhoven B,Kuiper M,Sluis-Cremer N,Harrigan PR,Tachedjian G |
|
Evidence
|
N348I appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs) M41L and T215Y/F (p < 0.001), the lamivudine resistance mutations M184V/I (p < 0.001), and non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p < 0.001).
|
|
|
HIV Mutation Detail Information